Hale Center Publications
Qiang L, Hoffman MT, Chun JH, Parent B, Hambitzer F, Peprah F, Kureshi CTS, Lim BS, Chang E, Walsh MJ, Tello JG, Atajanova T, Shin H, Perkins C, Kureshi R, Molina-Aponte Y, Dougan JM, Zuo C, Brais L, Clancy TE, Cleary JM, Hornick JL, Huffman BM, Mancias JD, Molina G, Fairweather M, Nowak JA, Perez KJ, Rubinson DA, Slater S, van Dams R, Wang J, Wolpin BM, Wong KK, Singh H, Aguirre AJ, Baker D, Dougan M, Dougan SK. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Cell. 2026 Sep 23:S0092-8674(26)01018-4. doi: 10.1016/j.cell.2026.08.045. Epub ahead of print. PMID: 42777708.
Karam J, Hoffman SE, Garza A, Gui D, Hoffman HI, Titchen BM, Tanaka Y, Pimenta E, Pappa T, Valderrabano L, Bi K, Gillani R, Brais L, Shannon E, Hornick JL, Park J, Chan J, Van Allen EM. Conserved neuronal-like and secretory programs define the spatial architecture of gastroenteropancreatic neuroendocrine tumors. J Clin Invest. 2026 Sep 1:e204119. doi: 10.1172/JCI204119. Epub ahead of print. PMID: 42678737.
Aronchik I, Kar S, Zhuang Y, Ahler E, Lai LP, Seshadri V, Yang YC, Bulle A, Menard M, Nayak B, Labrecque MP, Dilly J, Kim E, Jiang L, Yano J, Wasko UN, Helland C, Bredeson S, Garrick B, Gindin Y, Sickler B, Wei X, Seamon K, Jiang J, Lim KH, Holderfield M, Quintana E, Hegde A, Salman Z, Starodub A, Spira A, Park W, Hong DS, Barve M, Pelster M, Sommerhalder D, Punekar SR, Garrido-Laguna I, Wolpin BM, Maitra A, Gustafson WC, Kelsey S, Smith JAM, Lin KK, Aguirre AJ, Singh M. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat Med. 2026 Aug;32(8):2865-2877. doi: 10.1038/s41591-026-04537-w. Epub 2026 Aug 11. PMID: 42581230; PMCID: PMC13472880.
Neiswender JV, Maffa S, Brenan L, ElHarouni D, Yun Y, Boyle I, Wienand K, Inam H, Bertea T, Anderson A, Wong M, Enriquez M, Lenz E, Villafranca B, Shanks N, Hager M, Lloyd N, Shadmany H, Wie SJ, Liang H, Yunghans K, Zhang X, Golden L, Harris H, Day S, Montgomery P, Stokes S, Giglio RM, Hajal C, Whittle JR, Garcia G, Mills CE, Touat M, Pelton K, Li H, Prabhakar PS, Herter S, Kamrat ZH, Gui D, Dilly J, Wong CK, Guo JA, Pal S, Baidi Y, Johnston R, Brown DD, Bhatia S, Winter PS, Raghavan S, Beroukhim R, Colas E, Spector DL, Bass AJ, Sorger PK, Chen Y, Hill SJ, Oesterreich S, Lee AV, Beltran H, Boehm JS, Tseng YY, Root DE, Hahn WC, Aguirre AJ, Campbell CD, Ligon KL, Dempster JM, Shibue T, Vazquez F. A dependency map enhanced with next-generation 3D cancer models. Nature. 2026 Sep;657(8132):789-799. doi: 10.1038/s41586-026-10843-7. Epub 2026 Aug 5. PMID: 42557315; PMCID: PMC13581591.
Parent BD, Kelly AE, Hoffman MT, Dougan M, Aguirre AJ, Dougan SK. Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Immunother Adv. 2026 Jul 15;6(1):ltag013. doi: 10.1093/immadv/ltag013. PMID: 42500327; PMCID: PMC13398997
Biancur DE, Venkatesh H, Crawford A, Jeong Y, Sohn ASW, Kapner KS, Yamamoto K, Lin EY, Banh RS, Assi M, Shapiro B, Yu P, Song SC, Coetzee WA, Aguirre AJ, Jones AN, Kimmelman AC, Possemato R. Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis. Sci Adv. 2026 Jul 17;12(29):eadz8681. doi: 10.1126/sciadv.adz8681. Epub 2026 Jul 17. PMID: 42467776; PMCID: PMC13378540.
Surana R, Perez KJ. Going beyond total skeletal muscle area at L3 (tSMA) to accurately assess pancreatic cancer cachexia. J Gastrointest Oncol. 2026 Jun 30;17(3):191. doi: 10.21037/jgo-2026-0221. Epub 2026 Jun 25. PMID: 42434244; PMCID: PMC13350469.
Gültekin Y, Vander Heiden MG. Local signals, systemic decline. Science. 2026 Jul 2;393(6806):33-34. doi: 10.1126/science.aej0415. Epub 2026 Jul 2. PMID: 42391391.
Shen Q, Mobley C, Wang M, Ferrari P, Adami HO, Afshar N, Babic A, van den Brandt PA, Cheng E, Eliassen AH, Fung TT, Giovannucci EL, Hirabayashi M, Hou T, Huang BZ, Huang WY, Joshu CE, Kanehara R, Katzke V, Lacey JV Jr, Landry MJ, Larsson SC, Liao LM, Martinez ME, McCullough ML, Miller AB, Milne RL, Moore SC, Mucci LA, Naudin S, Prizment A, Park SY, Rohan TE, Riboli E, Robien K, Sandin S, Sawada N, Shams-White MM, Sinha R, Smith-Byrne K, Stampfer MJ, Stolzenberg-Solomon RZ, Um CY, Visvanathan K, Wang SS, Weiderpass E, White E, Willett WC, Wolk A, Wolpin BM, Yuan C, Smith-Warner SA, Genkinger JM. Adherence to the Mediterranean diet and risk of pancreatic cancer: an analysis of 2.3 million participants in the Pooling Project of Prospective Studies of Diet and Cancer (DCPP). Eur J Epidemiol. 2026 Jun 25. doi: 10.1007/s10654-026-01418-x. Epub ahead of print. PMID: 42348090.
Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KS, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Kalkat M, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, Der CJ. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 2026 Jun 17;45(7):117627. doi: 10.1016/j.celrep.2026.117627. Epub ahead of print. Erratum for: Cell Rep. 2021 Jun 29;35(13):109291. doi: 10.1016/j.celrep.2021.109291. PMID: 42308106.
Ludvigsson JF, Sun J, Yuan C, Vujasinovic M, Löhr JM, Wolpin BM, Wang QL. Risk of pancreatic cancer associated with precursor lesions in individuals and first-degree relatives: a nationwide cohort study. Clin Gastroenterol Hepatol. 2026 Jun 15:S1542-3565(26)00443-X. doi: 10.1016/j.cgh.2026.06.009. Epub ahead of print. PMID: 42297317.
DenAdel A, Hughes M, Thoutam A, Gupta A, Navia AW, Fusi N, Raghavan S, Winter PS, Amini AP, Crawford L. Evaluating the role of pretraining dataset size and diversity on single-cell foundation model performance. Nat Methods. 2026 Jul;23(7):1447-1457. doi: 10.1038/s41592-026-03120-y. Epub 2026 Jun 9. PMID: 42265208.
Lin EY, Mukhopadhyay S, Corcoran D, Assi M, Encarnación Rosado J, Sohn ASW, Biancur DE, Yu P, Deng J, Chen T, Wong KK, Dougan SK, Kimmelman AC. Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells. Cancer Res. 2026 Jun 1. doi: 10.1158/0008-5472.CAN-25-2451. Epub ahead of print. PMID: 42224631.
O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2605555. Epub ahead of print. PMID: 42223072.
Perez KJ, Dias Costa A, Jordan A, Karasic TB, Elganainy D, Kim S, Yuan C, Gui DY, Tan R, Hong SC, Wang X, Cristea S, Coleman E, Truitt M, Oh TG, Zheng H, Furniss CS, Brais L, Bird A, Remland J, Gocheva V, Thalappillil JS, Anderson M, Cleary JM, Enzinger A, Giannakis M, Ng K, Rubinson DA, Schlechter B, Surana R, Singh H, Abrams T, Teitelbaum U, Izgur N, Allen E, Winter PS, Raghavan S, Yeh JJ, Von Hoff D, Liddle C, Downes M, Evans RM, O'Dwyer P, Aguirre A, Nowak JA, Wolpin BM. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Nat Cancer. 2026 May 25. doi: 10.1038/s43018-026-01165-8. Epub ahead of print. PMID: 42185478.
Grabski IN, Schneider JL, Hanahan S, Ravi A, Gainor JF, Haigis KM, Irizarry RA, Haigis MC. Aging dictates tumor-specific genomic alterations across cancer types. NPJ Aging. 2026 May 12. doi: 10.1038/s41514-026-00392-8. Epub ahead of print. PMID: 42120871.
Kureshi CTS, Walsh MJ, Kureshi R, Cardot-Ruffino V, Agardy DA, Ali LR, Dougan JM, Qiang L, Shen J, Zuo C, Lenehan PJ, Wang SJ, Chang E, Remland J, Brais L, Clancy TE, Cleary JM, Hornick JL, Huffman BM, Mancias JD, Molina G, Fairweather M, Nowak JA, Perez KJ, Rubinson DA, Slater S, van Dams R, Wang J, Wolpin BM, Zhao L, Barrientos K, Novosiadly R, Broz M, Singh H, Dougan M, Dougan SK. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer Cell. 2026 May 7:S1535-6108(26)00216-3. doi: 10.1016/j.ccell.2026.04.005. Epub ahead of print. PMID: 42102812.
Gong D, Guo JA, Su J, Cetinkaya S, Hennessey C, Yu P, Jambhale A, Wang PL, Caldwell NJ, Lam A, Wang J, Shiau C, Kapner KS, Dilly J, Abbassi L, Chugh S, Dasgupta S, Nowak J, Wolpin BM, Zhang ML, Mino-Kenudson M, Jacks T, Aguirre AJ, Hwang WL. GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell Rep. 2026 May 26;45(5):117314. doi: 10.1016/j.celrep.2026.117314. Epub 2026 Apr 27. PMID: 42048185.
Srinivas Rao S, Song OK, Noda Y, Khurschid KS, Rosenthal MH, Kambadakone AR. Pancreatic Cancer Screening and Early Detection: Current Strategies and Emerging Innovations in Imaging. Radiol Clin North Am. 2026 May;64(3):489-499. doi: 10.1016/j.rcl.2026.01.005. Epub 2026 Mar 6. PMID: 42020073.
Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou SHI, Lin T, Kar S, Tao L, Vora R, Hegde A, Aung K, Hong DS. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026 May 7;394(18):1790-1802. doi: 10.1056/NEJMoa2505783. PMID: 42090791.
Oberg AL, Bamlet WR, Izmirlian G, Balasenthil S, Batra SK, Hayashi M, Herman DS, Hollingsworth MA, Jain M, Killary AM, Krusen BM, Liu S, Majumder S, Natarajan G, Sen S, Smith LM, Srivastava S, Wolpin BM, Zaret KS, Goggins MG. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase 2 blinded biomarker validation and panel discovery study. Clin Cancer Res. 2026 Mar 23. doi: 10.1158/1078-0432.CCR-25-4061. Epub ahead of print. PMID: 41870276.
Ferreira S, Flowers BM, Choi WY, Farina-Morillas M, Gatto A, Bhattacharyya S, Boross G, Hassan G, Mulligan AS, Vogel H, Wood LD, Weaver VM, Winslow MM, Petrov DA, Sherman MH, Choi HY, Hayes DN, Aguirre AJ, Seoane JA, Attardi LD. Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment. Cancer Res. 2026 Mar 11. doi: 10.1158/0008-5472.CAN-25-1969. Epub ahead of print. PMID: 41811433.
Assi M, Wang R, Kawaler EA, Sohn ASW, Zahidunnabi Dewan M, Kalfakakou D, Encarnacion-Rosado J, Kapner KS, Ganguly K, Paulo JA, Simeone DM, Aguirre AJ, Banh RS, Kimmelman AC. Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell. 2026 Mar 19;189(6):1731-1747.e25. doi: 10.1016/j.cell.2025.12.053. Epub 2026 Feb 16. PMID: 41702399.
McDonald TO, Bruno S, Roney JP, Zervantonakis IK, Michor F. BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug Responses. Cancer Res. 2026 Mar 2;86(5):1286-1299. doi: 10.1158/0008-5472.CAN-25-1181. PMID: 41248483.
Frisch A, Martin E, Cannon T, Wadlow R, Raghavan S, Sen T, Karim NA. Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies. Curr Oncol. 2026 Mar 3;33(3):148. doi: 10.3390/curroncol33030148. PMID: 41892176; PMCID: PMC13024909.
Nwizu C, Hughes M, Ramseier ML, Navia AW, Shalek AK, Fusi N, Raghavan S, Winter PS, Amini AP, Crawford L. Scalable nonparametric clustering with unified marker gene selection for single-cell RNA-seq data. Cell Rep Methods. 2026 Mar 23;6(3):101329. doi: 10.1016/j.crmeth.2026.101329. Epub 2026 Mar 12. PMID: 41825449; PMCID: PMC13030991.
Johnson CW, Oladimeji R, O'Donohue E, Haigis KM. The Neomorphic Chemistry of KRAS Autophosphorylation Is Dynamically Regulated by Active Site Conformation. ACS Chem Biol. 2026 Mar 30. doi: 10.1021/acschembio.6c00157. Epub ahead of print. PMID: 41906856.
Rodriguez GE, Zhao Y, Nishiga Y, Peprah F, Shen J, Abhiraman GC, Ogishi M, Zhang C, Saco J, Waghray D, Serasanambati M, Torres L, Simone BW, Su L, Wilson SC, Yang A, Sun Q, Picton L, Saxton RA, Bhandarkar V, Lee MJ, Andrews E, Jiang H, Obenaus M, Yen M, Atajanova T, Blish CA, Spranger S, Wherry EJ, Kirane A, Ribas A, Raulet DH, Kalbasi A, Dougan SK, Dougan M, Sage J, Garcia KC. Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics. Science. 2026 Feb 19:eadx9954. doi: 10.1126/science.adx9954. Epub ahead of print. PMID: 41712697.
Assi M, Wang R, Kawaler EA, Sohn ASW, Zahidunnabi Dewan M, Kalfakakou D, Encarnacion-Rosado J, Kapner KS, Ganguly K, Paulo JA, Simeone DM, Aguirre AJ, Banh RS, Kimmelman AC. Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell. 2026 Feb 16:S0092-8674(25)01502-8. doi: 10.1016/j.cell.2025.12.053. Epub ahead of print. PMID: 41702399.
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM. A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Clin Cancer Res. 2025 Feb 13. doi: 10.1158/1078-0432.CCR-24-3766. Epub ahead of print. PMID: 41686836.
Cheng HH, Giri VN, Goggins M, Yurgelun MB, Karlan BY, Norquist BS, Daly MB, Pal T, AlHilli Z, Arun B, Churpek J, Colonna S, Domchek SM, Escobar MR, Fejerman L, Friedman S, Hagemann A, Hendrix A, Huo D, Hutton ML, Kassem N, Khan S, Kurian AW, Laronga C, Mak JS, Maxwell KN, McDonnell K, Merajver SD, Mersch J, Offit K, Plichta J, Rash D, Reiser G, Senter-Jamieson L, Shannon KM, Welborn J, Wick MJ, Wood M, Darlow S, Diwan Z, Dwyer M. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026. J Natl Compr Canc Netw. 2026 Feb;24(2):2-10. doi: 10.6004/jnccn.2026.0007. PMID: 41671423.
Jun H, Tanaka Y, Johri S, Camp SY, Bao EL, Carvalho FLF, Gui DY, Jordan AC, Labaki C, Martin SD, Nagy M, O'Meara TA, Pappa T, Pimenta EM, Saad E, Yang DD, Gillani R, Tewari AK, Reardon B, Van Allen E. A context-augmented large language model for accurate precision oncology medicine recommendations. 2026 Mar 9;44(3):676-685.e4. doi: 10.1016/j.ccell.2025.12.017. Epub 2026 Jan 15. PMID: 41544626; PMCID: PMC12811686.
Reardon B, Culhane AC, Van Allen EM. Convergence of machine learning and genomics for precision oncology. Nat Rev Cancer. 2026 Jan 2. doi: 10.1038/s41568-025-00897-6. Epub ahead of print. PMID: 41478861.
Aney KJ, Jeong WJ, Koak P, Ohman AW, Nguyen CH, Wolpin BM, Nowak JA, Nissim S. Novel Acinar Metaplastic States Uncovered in Exocrine Pancreas Disease. Cell Mol Gastroenterol Hepatol. 2025 Dec 24:101717. doi: 10.1016/j.jcmgh.2025.101717. Epub ahead of print. PMID: 41453639.
Ozawa H, Takahashi K, Motegi T, Jacobi J, Bhattarchya A, Shigeta K, Takamori S, Onishi M, Luan Z, Fukuda K, Ueno A, Kitago M, Kawakubo H, Kitagawa Y, Keith D, Muschler J, Sears RC, Long MD, Mancias JD, Aguirre AJ, Kufe D. Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. Clin Cancer Res. 2025 Dec 15;31(24):5246-5260. doi: 10.1158/1078-0432.CCR-25-2333. PMID: 41086055; PMCID: PMC12703357.
McDonald TO, Bruno S, Roney JP, Zervantonakis IK, Michor F. BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug Responses. Cancer Res. 2025 Nov 17. doi: 10.1158/0008-5472.CAN-25-1181. Epub ahead of print. PMID: 41248483.
Long SA, Todd H, Goodhart G, Chang WH, Amparo AM, Bridgens R, Dilly J, Park SJ, Beal RM, Shehadeh SM, Satyadi MA, Trivedi VK, Ackermann SE, Mukherjee R, Goodwin CM, Edwards AC, Stalnecker CA, Greis KD, Aguirre AJ, Hobbs GA, Bryant KL, Ahmad SA, Cox AD, Der CJ, Waters AM. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Cancer Res. 2025 Nov 17. doi: 10.1158/0008-5472.CAN-25-1835. Epub ahead of print. PMID: 41248420.
Aajja E, Lefort H, Mahibullah S, Leclercq M, Aney KJ, Nissim S, Nguyen L, Chariot A, Henriet P, Tyteca D, Close P, Pierreux CE. Upregulation of ELP3 in acinar cells during acute pancreatitis is dispensable for homeostasis, inflammation, regeneration, and cancer initiation. Sci Rep. 2025 Nov 6;15(1):38976. doi: 10.1038/s41598-025-22849-8. PMID: 41198876; PMCID: PMC12592441.
Carstens EJ, Takahashi K, Sakamoto N, De Vizio M, Morgado M, Nikkhoi SK, Mangipudi A, Nguyen CH, Weltzin T, Nakayama I, Lv Q, Zeng J, Nie C, Deng C, Wang X, Liu L, Klempner SJ, Ramasubramanian A, Nowak JA, Aguirre AJ, Shitara K, Smith EL. Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat Commun. 2025 Nov 1;16(1):9651. doi: 10.1038/s41467-025-65148-6. PMID: 41176582; PMCID: PMC12579598.
Chun JH, Lim BS, Roy S, Walsh MJ, Abhiraman GC, Zhangxu K, Atajanova T, Revach OY, Clark EC, Li P, Palin CA, Khanna A, Tower S, Kureshi R, Hoffman MT, Sharova T, Lawless A, Cohen S, Boland GM, Nguyen T, Peprah F, Tello JG, Liu SY, Kim CJ, Shin H, Quijano-Rubio A, Jude KM, Gerben S, Murray A, Heine P, DeWitt M, Ulge UY, Carter L, King NP, Silva DA, Kueh HY, Kalia V, Sarkar S, Jenkins RW, Garcia KC, Leonard WJ, Dougan M, Dougan SK, Baker D. Design of a potent interleukin-21 mimic for cancer immunotherapy. Sci Immunol. 2025 Sep 26;10(111):eadx1582. doi: 10.1126/sciimmunol.adx1582. Epub 2025 Sep 26. PMID: 41004565.
Alessi JV, Lindsay JR, Giobbie-Hurder A, Sharma B, Felt K, Kumari P, Mazor T, Cerami E, Lotter W, Altreuter J, Weirather J, Dryg I, Hoebel K, Manos M, Adib E, Curtis JD, Ricciuti B, Di Federico A, Ghandour F, Saad E, Wang XA, Pecci F, Holovatska M, Gandhi MM, Hughes ME, O'Meara TA, Chan SJ, Pfaff K, Konstantinopoulos PA, Hodi FS, Shipp MA, Signoretti S, Choueiri T, Wei XX, Santagata S, Hanna GJ, Lin NU, Tolaney SM, Liu J, Sorger PK, Lindeman N, Sholl LM, Nowak JA, Barbie D, Awad MM, Johnson BE, Rodig SJ. Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors. JCO Precis Oncol. 2025 Sep;9:e2500240. doi: 10.1200/PO-25-00240. Epub 2025 Sep 4. PMID: 40906987.
Surana R, Morgado M, Somasundaram A, Bockorny B, Weekes CD, Coleman EC, Bird A, Wang J, Williams HL, Zheng H, Brais LK, Saxena N, Graham C, Ritterband L, Sawin M, Peters ML, Whooley P, Bullock A, Zerillo J, Sanoff HK, Clark JW, Parikh AR, Yurgelun MB, Patel AK, Mayer RJ, Cleary JM, Enzinger P, Rubinson DA, McCleary NJ, Enzinger A, Slater S, Ng K, Biller LH, Abrams TA, Huffman BM, Singh H, Raghavan S, Mancias JD, Bryant KL, Nowak JA, Aguirre AJ, Der CJ, Wolpin BM, Perez K. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer. JCO Precis Oncol. 2025 Sep;9:e2500332. doi: 10.1200/PO-25-00332. Epub 2025 Sep 2. PMID: 40893054.
Guo JA, Gong D, Evans K, Takahashi K, Jambhale AD, Shiau C, Yu P, Wang S, Wu WW, Chugh S, Kapner KS, Dilly J, Zhao D, Chen P, Smith EL, Mancias JD, Vazquez F, Singh H, Hwang WL, Aguirre AJ. Integrative genomic identification of therapeutic targets for pancreatic cancer. Cell Rep. 2025 Aug 21;44(9):116191. doi: 10.1016/j.celrep.2025.116191. Epub ahead of print. PMID: 40848256.
Zhang H, Santana-Codina N, Yu Q, Poupault C, Campos C, Qin X, Sindoni N, Ciscar M, Padhye A, Kuljanin M, Wang J, Dorman MJ, Bross P, Aguirre AJ, Dougan SK, Sarosiek KA, Mancias JD. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. Nat Commun. 2025 Jul 30;16(1):6987. doi: 10.1038/s41467-025-61242-x. PMID: 40738904; PMCID: PMC12311037.
Weller C, Burnett GL, Jiang L, Chakraborty S, Zhang D, Vita NA, Dilly J, Kim E, Maldonato B, Seamon K, Eilerts DF, Milin A, Marquez A, Spradlin J, Helland C, Gould A, Ziv TB, Dinh P, Steele SL, Wang Z, Mu Y, Chugh S, Feng H, Hennessey C, Wang J, Roth J, Rees M, Ronan M, Wolpin BM, Hahn WC, Holderfield M, Wang Z, Koltun ES, Singh M, Gill AL, Smith JAM, Aguirre AJ, Jiang J, Knox JE, Wildes D. A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors. Science. 2025 Jul 24;389(6758):eads0239. doi: 10.1126/science.ads0239. Epub 2025 Jul 24. PMID: 40705880.
Knoll N, Masser S, Bordas B, Ebright RY, Li G, Kesar D, Destefanis E, Kania N, Rodriguez DJ, Jen J, Zagar SE, Mensah C, Chen Z, Moffitt SJ, Enakireru EM, He Y, Feng B, Chokshi MK, Jin CY, Raghavan S, Sellers WR, Mulvaney KM. CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-deleted Cancer. Cancer Res. 2025 Jul 22. doi: 10.1158/0008-5472.CAN-25-1464. Epub ahead of print. PMID: 40694540.
Liu SY, Hulsman MPM, Leyendecker P, Chang E, Donovan KA, Strobel F, Dougan J, Fischer ES, Dougan M, Dougan SK, Qiang L. SMAC mimetics induce human macrophages to phagocytose live cancer cells. Immunother Adv. 2025 Jul 9;5(1):ltaf026. doi: 10.1093/immadv/ltaf026. PMID: 40756608; PMCID: PMC12314603.
Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract. 2025 May 9:OP2500133. doi: 10.1200/OP-25-00133. Epub ahead of print. PMID: 40344544.
Ely ZA, Kulstad ZJ, Gunaydin G, Addepalli S, Verzani EK, Casarrubios M, Clauser KR, Wang X, Lippincott IE, Louvet C, Schmitt T, Kapner KS, Agus MP, Hennessey CJ, Cleary JM, Hadrup SR, Klaeger S, Su J, Jaeger AM, Wolpin BM, Raghavan S, Smith EL, Greenberg PD, Aguirre AJ, Abelin JG, Carr SA, Jacks T, Freed-Pastor WA. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science. 2025 May 8;388(6747):eadk3487. doi: 10.1126/science.adk3487. Epub 2025 May 8. PMID: 40339010.
Gonzalo-Encabo P, Gardiner J, Norris MK, Wilson RL, Normann AJ, Nguyen D, Parker N, Tjogas D, Brais LK, Meyerhardt JA, Rosenthal MH, Wolpin BM, Uno H, Dieli-Conwright CM. Resistance exercise combined with protein supplementation for skeletal muscle mass in people with pancreatic cancer undergoing neoadjuvant chemotherapy: Study protocol for the REBUILD trial. PLoS One. 2025 May 2;20(5):e0322192. PMID: 40315221; PMCID: PMC12047797.
Ebright RY, Dilly J, Shaw AT, Aguirre AJ. Response and Resistance to RAS Inhibition in Cancer. Cancer Discov. 2025 Apr 28:OF1-OF25. PMID: 40293709.
Yates J, Van Allen EM. New horizons at the interface of artificial intelligence and translational cancer research. Cancer Cell. 2025 Apr 14;43(4):708-727. PMID: 40233719; PMCID: PMC12007700.
Boyle K, Perez KJ. GEMPAX, do we have another second-line option after mFOLFIRINOX in pancreatic cancer? Ann Transl Med. 2025 Feb 28;13(1):9. PMID: 40115057; PMCID: PMC11921235.
Lau MC, Borowsky J, Väyrynen JP, Haruki K, Zhao M, Dias Costa A, Gu S, da Silva A, Ugai T, Arima K, Nguyen MN, Takashima Y, Yeong J, Tai D, Hamada T, Lennerz JK, Fuchs CS, Wu CJ, Meyerhardt JA, Ogino S, Nowak JA. Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironment. PLoS Comput Biol. 2025 Feb 18;21(2):e1012707. doi: 10.1371/journal.pcbi.1012707. PMID: 39965007; PMCID: PMC11849983.
Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008. PMID: 39908431.
Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025 Jan;25(1):59-73. doi: 10.1038/s41568-024-00763-x. Epub 2024 Oct 28. PMID: 39468210.
Cote GM, Kochupurakkal BS, Do K, Bullock A, Cheng ML, Muzikansky A, McLoughlin DE, Cleary JM, Gao X, Parikh A, Park JC, Weekes CD, Yeku O, Zou L, Shapiro GI. A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clin Cancer Res. 2025 Jan 6;31(1):35-44. doi: 10.1158/1078-0432.CCR-24-1867. PMID: 39453756.
Lien EC, Vu N, Westermark AM, Danai LV, Lau AN, Gültekin Y, Kukurugya MA, Bennett BD, Vander Heiden MG. Effects of Aging on Glucose and Lipid Metabolism in Mice. Aging Cell. 2024 Dec 27:e14462. doi: 10.1111/acel.14462. Epub ahead of print. PMID: 39731205.
Kureshi CT, Dougan SK. Cytokines in cancer. Cancer Cell. 2024 Dec 7:S1535-6108(24)00446-X. doi: 10.1016/j.ccell.2024.11.011. Epub ahead of print. PMID: 39672170.
Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the Cancer Dependency Map. Nat Rev Cancer. 2025 Jan;25(1):59-73. doi: 10.1038/s41568-024-00763-x. Epub 2024 Oct 28. PMID: 39468210.
Cote GM, Kochupurakkal BS, Do K, Bullock A, Cheng ML, Muzikansky A, McLoughlin DE, Cleary JM, Gao X, Parikh A, Park JC, Weekes CD, Yeku O, Zou L, Shapiro GI. A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clin Cancer Res. 2025 Jan 6;31(1):35-44. doi: 10.1158/1078-0432.CCR-24-1867. PMID: 39453756
Liu N, Kattan WE, Mead BE, Kummerlowe C, Cheng T, Ingabire S, Cheah JH, Soule CK, Vrcic A, McIninch JK, Triana S, Guzman M, Dao TT, Peters JM, Lowder KE, Crawford L, Amini AP, Blainey PC, Hahn WC, Cleary B, Bryson B, Winter PS, Raghavan S, Shalek AK. Scalable, compressed phenotypic screening using pooled perturbations. Nat Biotechnol. 2024 Oct 7. doi: 10.1038/s41587-024-02403-z. Epub ahead of print. PMID: 39375446.
Zhao M, Maitra A, Nowak JA. Big insights from small samples: uncovering the potential of EUS-guided FNAs in pancreatic cancer through predictive genomics and transcriptomics. EBioMedicine. 2024 Oct 5;109:105380. doi: 10.1016/j.ebiom.2024.105380. Epub ahead of print. PMID: 39369615; PMCID: PMC11490758.
Singh H, Xiu J, Kapner KS, Yuan C, Narayan RR, Oberley M, Farrell A, Surana R, Huffman BM, Perez K, Cleary JM, Jordan AC, Dias Costa A, Williams HL, Raghavan S, Weinberg B, Pishvaian MJ, Shroff R, Goel S, Dougan SK, Nowak JA, Spetzler D, Sledge G, Wolpin BM, Aguirre AJ. Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer. Clin Cancer Res. 2024 Sep 16. doi: 10.1158/1078-0432.CCR-24-1164. Epub ahead of print. PMID: 39283131.
Aguirre AJ, Stanger BZ, Maitra A. Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer. Cancer Res. 2024 Sep 16;84(18):2950-2953. doi: 10.1158/0008-5472.CAN-24-1926. PMID: 39279379.
Sivanand S, Gultekin Y, Winter PS, Vermeulen SY, Tchourine KM, Abbott KL, Danai LV, Gourgue F, Do BT, Crowder K, Kunchok T, Lau AN, Darnell AM, Jefferson A, Morita S, Duda DG, Aguirre AJ, Wolpin BM, Henning N, Spanoudaki V, Maiorino L, Irvine DJ, Yilmaz OH, Lewis CA, Vitkup D, Shalek AK, Vander Heiden MG. Cancer tissue of origin constrains the growth and metabolism of metastases. Nat Metab. 2024 Aug 19. doi: 10.1038/s42255-024-01105-9. Epub ahead of print. PMID: 39160333.
Nguyen TTP, Mancias JD. Methods for Monitoring NCOA4-Mediated Ferritinophagy. Methods Mol Biol. 2024;2845:177-189. doi: 10.1007/978-1-0716-4067-8_14. PMID: 39115666.
Oberstein PE, Dias Costa A, Kawaler EA, Cardot-Ruffino V, Rahma OE, Beri N, Singh H, Abrams TA, Biller LH, Cleary JM, Enzinger P, Huffman BM, McCleary NJ, Perez KJ, Rubinson DA, Schlechter BL, Surana R, Yurgelun MB, Wang SJ, Remland J, Brais LK, Bollenrucher N, Chang E, Ali LR, Lenehan PJ, Dolgalev I, Werba G, Lima C, Keheler CE, Sullivan KM, Dougan M, Hajdu C, Dajee M, Pelletier MR, Nazeer S, Squires M, Bar-Sagi D, Wolpin BM, Nowak JA, Simeone DM, Dougan SK. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor. Cancer Immunol Res. 2024 Sep 3;12(9):1221-1235. doi: 10.1158/2326-6066.CIR-23-1073. PMID: 38990554.
Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta S, Uribe GA, Yang A, Kapner KS, Hambitzer FP, Qiang L, Feng H, Geisberg J, Wang J, Evans KE, Lyu H, Schalck A, Feng N, Lopez AM, Bristow CA, Kim MP, Rajapakshe KI, Bahrambeigi V, Roth JA, Garg K, Guerrero PA, Stanger BZ, Cristea S, Lowe SW, Baslan T, Van Allen EM, Mancias JD, Chan E, Anderson A, Katlinskaya YV, Shalek AK, Hong DS, Pant S, Hallin J, Anderes K, Olson P, Heffernan TP, Chugh S, Christensen JG, Maitra A, Wolpin BM, Raghavan S, Nowak JA, Winter PS, Dougan SK, Aguirre AJ. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024 Jul 8. doi: 10.1158/2159-8290.CD-24-0177. Epub ahead of print. PMID: 38975874.
Boire A, Burke K, Cox TR, Guise T, Jamal-Hanjani M, Janowitz T, Kaplan R, Lee R, Swanton C, Vander Heiden MG, Sahai E. Why do patients with cancer die? Nat Rev Cancer. 2024 Jun 19. doi: 10.1038/s41568-024-00708-4. Epub ahead of print. PMID: 38898221.
Furtado LV, Bifulco C, Dolderer D, Hsiao SJ, Kipp BR, Lindeman NI, Ritterhouse LL, Temple-Smolkin RL, Zehir A, Nowak JA. Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer. J Mol Diagn. 2024 Jun 6:S1525-1578(24)00115-6. doi: 10.1016/j.jmoldx.2024.05.002. Epub ahead of print. PMID: 38851389.
Safyan RA, Kim E, Dekker E, Homs M, Aguirre AJ, Koerkamp BG, Chiorean EG. Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e438598. doi: 10.1200/EDBK_438598. PMID: 38781541.
Maoz A, Rodriguez NJ, Yurgelun MB, Syngal S. Gastrointestinal Cancer Precursor Conditions and Their Detection. Hematol Oncol Clin North Am. 2024 Aug;38(4):783-811. doi: 10.1016/j.hoc.2024.04.002. Epub 2024 May 17. PMID: 38760197.
Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, Winters IP, Salman Z, Blaj C, Menard M, Brodbeck J, Chen Z, Wei X, Rosen MJ, Gindin Y, Lee BJ, Evans JW, Chang S, Wang Z, Seamon KJ, Parsons D, Cregg J, Marquez A, Tomlinson ACA, Yano JK, Knox JE, Quintana E, Aguirre AJ, Arbour KC, Reed A, Gustafson WC, Gill AL, Koltun ES, Wildes D, Smith JAM, Wang Z, Singh M. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024 Jun 3;14(6):994-1017. doi: 10.1158/2159-8290.CD-24-0027. PMID: 38593348.
Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, Lee B, Orlen M, Tian S, Stalnecker CA, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Muonio K, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs WP, Hibshman PS, Amparo AM, Hennessey C, Rees MG, Ronan MM, Roth JA, Brodbeck J, Tomassoni L, Bakir B, Socci ND, Herring LE, Barker NK, Wang J, Cleary JM, Wolpin BM, Chabot JA, Kluger MD, Manji GA, Tsai KY, Sekulic M, Lagana SM, Califano A, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Lowe SW, Badgley MA, Aguirre AJ, Vonderheide RH, Stanger BZ, Baslan T, Der CJ, Singh M, Olive KP. Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07379-z. Epub ahead of print. PMID: 38588697.
Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07205-6. Epub ahead of print. PMID: 38589574.
Corcoran RB, Do KT, Kim JE, Cleary JM, Parikh AR, Yeku OO, Xiong N, Weekes CD, Veneris J, Ahronian LG, Mauri G, Tian J, Norden BL, Michel AG, Van Seventer EE, Siravegna G, Camphausen K, Chi G, Fetter IJ, Brugge JS, Chen HX, Takebe N, Penson RT, Juric D, Flaherty KT, Sullivan RJ, Clark JW, Heist RS, Matulonis UA, Liu JF, Shapiro GI. Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3135. Epub ahead of print. PMID: 38456660.
Ko AH, Coveler AL, Schlechter BL, Bekaii-Saab T, Wolpin BM, Clark JW, Bockorny B, Bai LY, Lin YC, Chiang E, Langecker P, Lin SY. A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer. Invest New Drugs. 2024 Apr;42(2):221-228. doi: 10.1007/s10637-024-01430-6. Epub 2024 Mar 5. PMID: 38441850.
Aney KJ, Jeong WJ, Vallejo AF, Burdziak C, Chen E, Wang A, Koak P, Wise K, Jensen K, Pe'er D, Dougan SK, Martelotto L, Nissim S. A Novel Approach for Pancreas Transcriptomics Reveals the Cellular Landscape in Homeostasis and Acute Pancreatitis. Gastroenterology. 2024 Feb 5:S0016-5085(24)00130-6. doi: 10.1053/j.gastro.2024.01.043. Epub ahead of print. PMID: 38325760.
Wang QL, Babic A, Rosenthal MH, Lee AA, Zhang Y, Zhang X, Song M, Rezende LFM, Lee DH, Biller L, Ng K, Giannakis M, Chan AT, Meyerhardt JA, Fuchs CS, Eliassen AH, Birmann BM, Stampfer MJ, Giovannucci EL, Kraft P, Nowak JA, Yuan C, Wolpin BM. Cancer Diagnoses After Recent Weight Loss. JAMA. 2024 Jan 23;331(4):318-328. doi: 10.1001/jama.2023.25869. PMID: 38261044; PMCID: PMC10807298.
Ben-Ami R, Wang QL, Zhang J, Supplee JG, Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M, Babic A, Irajizad E, Davidi T, Zick A, Hubert A, Neiman D, Piyanzin S, Gal-Rosenberg O, Horn A, Shemer R, Glaser B, Boos N, Jajoo K, Lee L, Clancy TE, Rubinson DA, Ng K, Chabot JA, Kastrinos F, Kluger M, Aguirre AJ, Jänne PA, Bardeesy N, Stanger B, O'Hara MH, Till J, Maitra A, Carpenter EL, Bullock AJ, Genkinger J, Hanash SM, Paweletz CP, Dor Y, Wolpin BM. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2023 Dec 13:gutjnl-2023-331074. PMID: 38123998.
Kureshi R, Bello E, Kureshi CTS, Walsh MJ, Lippert V, Hoffman MT, Dougan M, Longmire T, Wichroski M, Dougan SK. DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity Sci Adv. 2023 Nov 24;9(47). PMID: 38000024; PMCID: PMC10672170.
Grabski IN, Heymach JV, Kehl KL, Kopetz S, Lau KS, Riely GJ, Schrag D, Yaeger R, Irizarry RA, Haigis KM. Effects of KRAS genetic interactions on outcomes in cancers of the lung, pancreas, and colorectum. Cancer Epidemiol Biomarkers Prev. 2023 Nov 9. PMID: 37943166.
Del Rivero J, Kennedy EB, Perez K. Systemic Therapy for Tumor Control in Well-Differentiated Metastatic Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Q and A. JCO Oncol Pract. 2023 Nov;19(11):955-958. PMID: 37774321.
Ali LR, Lenehan PJ, Cardot-Ruffino V, Dias Costa A, Katz MHG, Bauer TW, Nowak JA, Wolpin BM, Abrams TA, Patel A, Clancy TE, Wang J, Mancias JD, Reilley MJ, Stucky CH, Bekaii-Saab TS, Elias R, Merchant N, Slingluff CL Jr, Rahma OE, Dougan SK. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Clin Cancer Res. 2024 Feb 1;30(3):542-553. doi: 10.1158/1078-0432.CCR-23-1444. PMID: 37733830; PMCID: PMC10831338.
Wang QL, Babic A, Rosenthal MH, Lee AA, Zhang Y, Zhang X, Song M, Rezende LFM, Lee DH, Biller L, Ng K, Giannakis M, Chan AT, Meyerhardt JA, Fuchs CS, Eliassen AH, Birmann BM, Stampfer MJ, Giovannucci EL, Kraft P, Nowak JA, Yuan C, Wolpin BM. Cancer Diagnoses After Recent Weight Loss. JAMA. 2024 Jan 23;331(4):318-328. doi: 10.1001/jama.2023.25869. PMID: 38261044; PMCID: PMC10807298.
Ben-Ami R, Wang QL, Zhang J, Supplee JG, Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M, Babic A, Irajizad E, Davidi T, Zick A, Hubert A, Neiman D, Piyanzin S, Gal-Rosenberg O, Horn A, Shemer R, Glaser B, Boos N, Jajoo K, Lee L, Clancy TE, Rubinson DA, Ng K, Chabot JA, Kastrinos F, Kluger M, Aguirre AJ, Jänne PA, Bardeesy N, Stanger B, O'Hara MH, Till J, Maitra A, Carpenter EL, Bullock AJ, Genkinger J, Hanash SM, Paweletz CP, Dor Y, Wolpin BM. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2023 Dec 13:gutjnl-2023-331074. PMID: 38123998.
Kureshi R, Bello E, Kureshi CTS, Walsh MJ, Lippert V, Hoffman MT, Dougan M, Longmire T, Wichroski M, Dougan SK. DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity Sci Adv. 2023 Nov 24;9(47). PMID: 38000024; PMCID: PMC10672170.
Grabski IN, Heymach JV, Kehl KL, Kopetz S, Lau KS, Riely GJ, Schrag D, Yaeger R, Irizarry RA, Haigis KM. Effects of KRAS genetic interactions on outcomes in cancers of the lung, pancreas, and colorectum. Cancer Epidemiol Biomarkers Prev. 2023 Nov 9. PMID: 37943166.
Del Rivero J, Kennedy EB, Perez K. Systemic Therapy for Tumor Control in Well-Differentiated Metastatic Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Q and A. JCO Oncol Pract. 2023 Nov;19(11):955-958. PMID: 37774321.